<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942460</url>
  </required_header>
  <id_info>
    <org_study_id>FER-CA-IIT-001</org_study_id>
    <nct_id>NCT01942460</nct_id>
  </id_info>
  <brief_title>Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients</brief_title>
  <official_title>Use of FERAHEME® (Ferumoxytol) for Severe Chronic Kidney Disease and Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georges Ouellet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of ferumoxytol for the repletion of&#xD;
      iron stores and correction of iron deficiency anaemia in patients with severe chronic kidney&#xD;
      disease or end-stage chronic kidney disease on peritoneal dialysis, and to assess the impact&#xD;
      of the administration of a ferumoxytol dose on various markers for iron stores, as well as on&#xD;
      various markers for inflammation and oxidative stress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin, serum ferritin and transferrin saturation</measure>
    <time_frame>4 weeks following ferumoxytol administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory markers (C-reactive protein and Interleukin-6)</measure>
    <time_frame>60 minutes following ferumoxytol administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxidative stress markers (Malondialdehyde, Advance Oxidation Protein Products, Non Transferrin-bound Iron)</measure>
    <time_frame>60 minutes following ferumoxytol administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in soluble transferrin receptor</measure>
    <time_frame>4 weeks following ferumoxytol administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Iron-Deficiency Anemia</condition>
  <condition>Inflammation</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <other_name>Feraheme</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For women of childbearing age, negative serum pregnancy test at screening.&#xD;
&#xD;
          -  Severe chronic kidney disease (TFGe lower than 30 ml/min) OR end-stage kidney disease&#xD;
             on peritoneal dialysis.&#xD;
&#xD;
          -  Anaemia, as defined by haemoglobin (Hb) &lt; 120 g/L, within 14 days prior to screening,&#xD;
             in a patient with or without an Erythropoiesis-stimulating agent (ESA).&#xD;
&#xD;
          -  Iron depletion, as defined by transferrin saturation (TSAT) &lt; 20% and/or a ferritin&#xD;
             assay (FERR) &lt; 200, within 14 days prior to screening.&#xD;
&#xD;
          -  If an ESA is used, stable dose over the past 60 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to ferumoxytol or another intravenous iron formulation.&#xD;
&#xD;
          -  Administration of ferumoxytol or any other intravenous, intramuscular or oral iron&#xD;
             formulation within 30 days of enrolment.&#xD;
&#xD;
          -  Patient who have received a blood transfusion within 2 weeks prior to enrolment, or&#xD;
             are planned to receive a blood transfusion over the duration of the study.&#xD;
&#xD;
          -  Patient currently participating in a clinical trial with another investigational drug&#xD;
             or device or who have received an investigational drug or device within 30 days of&#xD;
             enrolment in this study.&#xD;
&#xD;
          -  Hb &lt; 90 g/L at the time of screening.&#xD;
&#xD;
          -  Existing or clinically suspected bleeding of digestive, gynaecological or other&#xD;
             origin.&#xD;
&#xD;
          -  Patient who have another cause of anemia, other than iron deficiency (for example, but&#xD;
             not limited to, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma,&#xD;
             myelodysplastic disorder, etc.).&#xD;
&#xD;
          -  Patients who are not responding to ESA or who are receiving in excess of 30000&#xD;
             units/week of erythropoietin (EPO), or 150 mcg/week of darbepoietin alfa.&#xD;
&#xD;
          -  Major surgery within one month prior to enrolment in the study or planned surgery,&#xD;
             other than vascular access creation, while the patient is in on the study.&#xD;
&#xD;
          -  Patient who have had a malignancy (except for non-melanoma cancer of the skin) unless&#xD;
             the patient has received curative treatment and has been disease-free for &gt; 2 years.&#xD;
&#xD;
          -  Patient who are considered by the Investigator to have a medical status that would&#xD;
             preclude the patient's participation in this protocol.&#xD;
&#xD;
          -  Patient due to have a magnetic resonance imaging examination or in whom such an&#xD;
             examination is planned, in the next three months.&#xD;
&#xD;
          -  Woman who plans to become pregnant in the next three months.&#xD;
&#xD;
          -  Woman that is breastfeeding.&#xD;
&#xD;
          -  Ongoing or recent (&lt; 2 weeks) bacterial infection requiring treatment.&#xD;
&#xD;
          -  Patient unable to give informed consent.&#xD;
&#xD;
          -  Patient refuses to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges Ouellet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Maisonneuve-Rosemont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Georges Ouellet</investigator_full_name>
    <investigator_title>Nephrologist</investigator_title>
  </responsible_party>
  <keyword>Iron</keyword>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

